Company Outlook & Guidance: Injectable companies (HIKMA, HOSIPORA, and Aurobindo) in the US market sales grew by ~4% YoY. We expect similar growth for GLAND in the core markets over a longer period and high single-digit growth in India and RoW over a long-term outlook.